| P50 | author | James Bruce Bussel | Q1680075 |
| | Andrzej Hellmann | Q9152201 |
| | Francesco Zaja | Q57307002 |
| | Jerzy Windyga | Q87941922 |
| | Jacek Trelinski | Q96097159 |
| | Alhossain A Khalafallah | Q47275556 |
| P2093 | author name string | Nichola Cooper | |
| | Donald M Arnold | |
| | Hany Zayed | |
| | Jiří Mayer | |
| | Anne-Marie Duliege | |
| | Liliya Sivcheva | |
| | Vadim Markovtsov | |
| | Wojciech Homenda | |
| | Elliot Grossbard | |
| P2860 | cites work | Immune thrombocytopenia | Q26830918 |
| | International consensus report on the investigation and management of primary immune thrombocytopenia | Q28262094 |
| | Fostamatinib for persistent/chronic adult immune thrombocytopenia. | Q54144290 |
| | Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud | Q54322103 |
| | Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis. | Q54488975 |
| | OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy | Q57752299 |
| | An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis | Q28294375 |
| | The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia | Q28305486 |
| | A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages | Q28634082 |
| | Advances in ITP--therapy and quality of life--a patient survey | Q28742871 |
| | Comprehensive analysis of kinase inhibitor selectivity | Q29616719 |
| | The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts | Q33332742 |
| | The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura | Q33360255 |
| | Long-term outcomes in adults with chronic ITP after splenectomy failure | Q33360520 |
| | Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. | Q33370619 |
| | The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. | Q33375450 |
| | Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). | Q33376235 |
| | Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura | Q33376373 |
| | Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura | Q33377602 |
| | Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial | Q33378523 |
| | Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group | Q33381983 |
| | Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. | Q33382517 |
| | Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial | Q33383374 |
| | Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives | Q33384139 |
| | Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome | Q33385999 |
| | Patient-reported treatment burden of chronic immune thrombocytopenia therapies | Q33400348 |
| | A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia | Q33415133 |
| | The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 |
| | The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation | Q38925714 |
| | Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials | Q40699579 |
| | In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib | Q41773428 |
| | Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents | Q43203308 |
| | TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis | Q44968896 |
| | Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 |
| | A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist | Q46568872 |
| | Splenectomy for Immune Thrombocytopenia: Down but not out. | Q47754303 |
| | GPIIb/IIIa autoantibody predicts better rituximab response in ITP. | Q48100314 |
| | Physician Decision Making in Selection of Second-Line Treatments in Immune Thrombocytopenia in Children. | Q52320502 |
| P433 | issue | 7 | |
| P921 | main subject | thrombocytopenia | Q585285 |
| | chronic immune thrombocytopenia | Q1088037 |
| | phase III clinical trial | Q42824827 |
| P304 | page(s) | 921-930 | |
| P577 | publication date | 2018-05-15 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials | |
| P478 | volume | 93 | |